Switch theme
Sign up to access all valuation multiples
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
1990
41.9K+
LTM Revenue $8.1B
LTM EBITDA $1.7B
$13.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ICON plc has a last 12-month revenue (LTM) of $8.1B and a last 12-month EBITDA of $1.7B.
In the most recent fiscal year, ICON plc achieved revenue of $8.3B and an EBITDA of $1.6B.
ICON plc expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ICON plc valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.1B | XXX | $8.3B | XXX | XXX | XXX |
| Gross Profit | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA | $1.7B | XXX | $1.6B | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $1.5B | XXX | $1.2B | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $1.1B | XXX | $791M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ICON plc's stock price is $130.
ICON plc has current market cap of $10.4B, and EV of $13.4B.
See ICON plc trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.4B | $10.4B | XXX | XXX | XXX | XXX | $13.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ICON plc has market cap of $10.4B and EV of $13.4B.
ICON plc's trades at 1.6x EV/Revenue multiple, and 8.6x EV/EBITDA.
Equity research analysts estimate ICON plc's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ICON plc has a P/E ratio of 9.2x.
See valuation multiples for ICON plc and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.4B | XXX | $10.4B | XXX | XXX | XXX |
| EV (current) | $13.4B | XXX | $13.4B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBIT | 8.7x | XXX | 11.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.2x | XXX | 13.1x | XXX | XXX | XXX |
| EV/FCF | 13.0x | XXX | 12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialICON plc's last 12 month revenue growth is -1%
ICON plc's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $29K for the same period.
ICON plc's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ICON plc's rule of X is 17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ICON plc and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $29K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ICON plc acquired XXX companies to date.
Last acquisition by ICON plc was XXXXXXXX, XXXXX XXXXX XXXXXX . ICON plc acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ICON plc founded? | ICON plc was founded in 1990. |
| Where is ICON plc headquartered? | ICON plc is headquartered in United States of America. |
| How many employees does ICON plc have? | As of today, ICON plc has 41.9K+ employees. |
| Who is the CEO of ICON plc? | ICON plc's CEO is Dr. Steven Cutler, PhD. |
| Is ICON plc publicy listed? | Yes, ICON plc is a public company listed on NAS. |
| What is the stock symbol of ICON plc? | ICON plc trades under ICLR ticker. |
| When did ICON plc go public? | ICON plc went public in 1998. |
| Who are competitors of ICON plc? | Similar companies to ICON plc include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of ICON plc? | ICON plc's current market cap is $10.4B |
| What is the current revenue of ICON plc? | ICON plc's last 12 months revenue is $8.1B. |
| What is the current revenue growth of ICON plc? | ICON plc revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of ICON plc? | Current revenue multiple of ICON plc is 1.6x. |
| Is ICON plc profitable? | Yes, ICON plc is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ICON plc? | ICON plc's last 12 months EBITDA is $1.7B. |
| What is ICON plc's EBITDA margin? | ICON plc's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of ICON plc? | Current EBITDA multiple of ICON plc is 8.0x. |
| What is the current FCF of ICON plc? | ICON plc's last 12 months FCF is $1.0B. |
| What is ICON plc's FCF margin? | ICON plc's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of ICON plc? | Current FCF multiple of ICON plc is 13.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
